Prevention First

Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.

Read more

Vaccine Market Access in the EU

How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access

Find out more

Vaccines Europe at a glance

Vaccines Europe acts as the cohesive voice of the Europe-based vaccine industry sector and is a trusted partner for public authorities. Find out more about our association and contribution to Europe.

Start Prezi

The vaccine industry
in figures

With 47% growth in R&D investment over the past eight years and over 70% of current R&D projects based on new antigens and new combinations, Vaccines Europe members highly contribute to innovation.

Find out more

An industry for healthy lives

As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe and is currently expanding to SMEs.
Find out more about our services, the opportunites we offer and how to become a member.

Find out how to become a member

Latest News

RSS

24 April – World Meningitis Day 2015

2015 04 24 Written by Vaccines Europe

Today is World Meningitis Day. It is estimated that every year more than 1.2 million people are affected by meningitis all around the world. Meningitis is inflammation of the meninges, the covering of the brain and spinal cord. It is most often caused by infection (bacterial, viral, or fungal), but can also be produced by chemical irritation, subarachnoid haemorrhage, cancer and other conditions. Meningitis is a serious disease that can affect anyone across all ages. According to the World Health Organisation (WHO) it is fatal in 50% of cases if untreated, and may result in brain damage, hearing loss or learning disability for survivors. Read more…

20-25 April 2015: This week is European Immunisation Week

2015 04 21 Written by Vaccines Europe

This week is European Immunisation Week. Immunisation is indeed considered one of the most cost-effective public health interventions available and the WHO estimates that it saves between 2 to 3 million lives every year. Vaccines has however become victims of their own success, and with the drop-down and disappearance of several diseases thanks to vaccination programmes many people who no longer see public health risks decide not to vaccinate. Over the past years, this has resulted in several severe outbreaks in European countries of vaccine preventable diseases putting avertable strains on health and healthcare systems. According to the WHO, “2013 saw 31865 measles cases alone in Europe, an increase of 348% compared to 2007. The cost of these outbreaks in both human and monetary terms is extremely high”. Read more…

IPROVE CONSORTIUM THIRD HIGH-LEVEL CONSULTATION MEETING ON RESEARCH & INNOVATION GAPS IN VACCINE RESEARCH TO CONVENE IN BRUSSELS ON 12-13 MARCH 2015

2015 03 12 Written by Vaccines Europe

Vaccines Europe (VE), The European Vaccine Initiative (EVI), The Sclavo Vaccines Association (SVA) and EATRIS due to meet in Brussels for penultimate workshop ahead of the final project summit with top stakeholders in the vaccine field.

Key opinion leaders in the field of vaccine research and development are meeting in the upcoming IPROVE consultation workshop in Brussels on 12 and 13 March 2015. The objective of the workshop is to formulate a consensus on future vaccine R&I activities and identify key gaps and needs to be addressed over the coming years to bolster vaccine innovation and connect across Europe the appropriate expertise needed to meet the challenge of current medical needs. Read more…

See all News